Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624371 · ClinicalTrials.gov registry record · Phase 1
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
A Phase 1 study of High Grade Glioma and Medulloblastoma, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT06624371: Recruiting Phase 1 study of High Grade Glioma and Medulloblastoma, sponsored by Emory University.
NCT06624371 is a Phase 1 study of High Grade Glioma and Medulloblastoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 18 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06624371, a Phase 1 study of High Grade Glioma and Medulloblastoma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.
Primary Outcome
Adverse events that meet definition of DLT and tolerability. The outcome will be evaluated by descriptive statistics. Rates of symptomatic and asymptomatic radiation necrosis will also be estimated for Stratum 1 patients.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Atovaquone
Study Locations (2)
Georgia
- Arthur M Blank Hospital - Atlanta
- Children's Healthcare of Atlanta: Scottish Rite - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT06624371 shows while recruiting
NCT06624371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (72% lower).
The record links to 4 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT06624371 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06624371 about?
NCT06624371 is a clinical study titled "Atovaquone Combined With Radiation in Children With Malignant Brain Tumors". The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/...
What is the current status of trial NCT06624371?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-03-28. Estimated completion is 2027-10.
What conditions does trial NCT06624371 study?
This clinical trial studies the following conditions: High Grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant.
What interventions are being tested in trial NCT06624371?
The interventions under investigation include: Radiation Therapy (RADIATION), Atovaquone (DRUG).
Who is sponsoring clinical trial NCT06624371?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624371 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06624371's enrollment target sits among peer trials
18 33rd of 42 higher than 8 of 42 other High Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
RECRUITING · Phase 1
-
STARLITE for Unresectable High-Grade Gliomas
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI